https://scholars.lib.ntu.edu.tw/handle/123456789/626335
標題: | Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics | 作者: | Chan M.-H Huang W.-T Satpathy A Su T.-Y Hsiao M RU-SHI LIU |
關鍵字: | FDA-proved drugs; Glioblastoma; Magnetic resonance imaging nanoparticles; Near-infrared phototherapy; Near-infrared probes | 公開日期: | 2022 | 卷: | 14 | 期: | 2 | 來源出版物: | Pharmaceutics | 摘要: | The most common malignant tumor of the brain is glioblastoma multiforme (GBM) in adults. Many patients die shortly after diagnosis, and only 6% of patients survive more than 5 years. Moreover, the current average survival of malignant brain tumors is only about 15 months, and the recurrence rate within 2 years is almost 100%. Brain diseases are complicated to treat. The reason for this is that drugs are challenging to deliver to the brain because there is a blood–brain barrier (BBB) protection mechanism in the brain, which only allows water, oxygen, and blood sugar to enter the brain through blood vessels. Other chemicals cannot enter the brain due to their large size or are considered harmful substances. As a result, the efficacy of drugs for treating brain diseases is only about 30%, which cannot satisfy treatment expectations. Therefore, researchers have designed many types of nanoparticles and nanocomposites to fight against the most common malignant tumors in the brain, and they have been successful in animal experiments. This review will discuss the application of various nanocomposites in diagnosing and treating GBM. The topics include (1) the efficient and long-term tracking of brain images (magnetic resonance imaging, MRI, and near-infrared light (NIR)); (2) breaking through BBB for drug delivery; and (3) natural and chemical drugs equipped with nanomaterials. These multifunctional nanoparticles can overcome current difficulties and achieve progressive GBM treatment and diagnosis results. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125335038&doi=10.3390%2fpharmaceutics14020456&partnerID=40&md5=5cab5a47a397d236c13dc71e68ab735a https://scholars.lib.ntu.edu.tw/handle/123456789/626335 |
ISSN: | 19994923 | DOI: | 10.3390/pharmaceutics14020456 |
顯示於: | 化學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。